Page 21 of 37: studies 401 to 420 of 725, newest first. Back to the depression overview
ACS Medicinal Chemistry Letters May 7, 2026 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel tricyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
Journal of Education, Health and Sport May 7, 2026 Kinga Zachar, M. Sito, Filip Jurkowski et al.
Introduction and purpose: Depressive disorders, particularly major depressive disorder (MDD) and treatment-resistant depression (TRD), remain major causes of disability worldwide. Conventional treatments are limited by delayed onset, incomplete response, relapse, and adverse effects. This review summarizes current evidence on the efficacy, safety, and durability of psilocybin-assisted therapy...
Cell Reports Medicine May 7, 2026 Mihai Avram, Aurore Menegaux, Felix Müller et al. 1 citation
The clinical trial NCT03866252 investigates the antidepressant effects of lysergic acid diethylamide (LSD) in 61 patients with major depressive disorder (MDD) randomized to low-dose LSD (LD-LSD; 2 × 25 μg) or moderate-to-high-dose LSD (HD-LSD; 100 μg followed by 200 μg) 4 weeks apart. Although the trial reports positive clinical outcomes, underlying mechanisms remain unclear. Here, we test...
Journal of Affective Disorders May 6, 2026 Rutger Boesjes, Claudia Oosterveld, Jeanine Kamphuis et al. 1 citation
Ketamine, including its enantiomers (S)-ketamine (esketamine) and (R)-ketamine (arketamine), has demonstrated rapid antidepressant effects in major depressive disorder (MDD) and bipolar disorder (BD), yet clinical responses vary widely, highlighting the need to identify mechanisms underlying treatment efficacy and related potential predictors. Growing evidence suggests that alterations in sleep...
ACS Chemical Neuroscience May 6, 2026 Maxemiliano V. Vargas, Cassandra J. Hatzipantelis, Lee E. Dunlap et al.
Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with...
Proceedings of the National Academy of Sciences May 5, 2026 Roberto Malinow
Ketamine has been shown to reduce depression and suicidality in individuals resistant to treatment by other drugs. Exactly how ketamine works is not known. Here, I propose a new hypothesis that involves synaptic and circuit plasticity and may lead to enhanced efficacy in treating depression as well as other conditions.
The Journal of Clinical Psychiatry May 4, 2026 Samuel T. Wilkinson, Brandon Kitay, Matthew Macaluso et al.
Background: Suicide is a public health crisis in the US, with limited evidence demonstrating efficacy of treatments for high-risk patients due in part to their exclusion from most clinical trials. This clinical trial evaluates the feasibility and efficacy of adjunctive cognitive behavioral therapy (CBT) with esketamine in patients with major depression and suicidal ideation (MDSI). Methods:...
The International Journal of Neuropsychopharmacology May 3, 2026 Kuan-I Liu, Wei-Chen Lin, Cheng-Ta Li et al.
Intravenous ketamine demonstrates rapid efficacy for treatment-resistant depression (TRD). However, its impact on individual depressive symptoms and whether the degree of treatment resistance moderates these effects remain unclear. This study aimed to dissect symptom-specific trajectories and examine the moderating role of the degree of treatment resistance. We conducted a post-hoc analysis of...
Human psychopharmacology May 2026 Juan Miguel Riestra, Yaxel Levin-Carrion, Roshan Sutar et al.
Treatment-resistant depression (TRD) remains a formidable challenge in psychiatry, with nearly one-third of patients with major depressive disorder (MDD) failing to respond adequately to first-line pharmacological treatments. Pathophysiology in MDD has highlighted the N-methyl-D-aspartate (NMDA) glutamatergic system as a promising therapeutic target. In 2022, the US Food and Drug Administration...
Journal of Nursing Scholarship May 2026 Wilawan Christraksa, Julia A Snethen, Julie L Ellis et al.
Spirituality is a crucial yet complex element of holistic nursing care, particularly when providing care for older adults with depression. In Thailand, depression poses a significant mental health challenge. Thai cultural values are deeply interwoven with individuals' beliefs, making spirituality a critical factor in addressing the care of older adults with depression. This study aimed to...
Health Psychology May 2026 Surenmaa Sukhbaatar, Shufang Sun, Matthew M Scarpaci et al.
This study evaluated the effects of the Mindfulness-Based Blood Pressure Reduction (MB-BP) program on depression symptoms in individuals with elevated blood pressure (BP). Exploratory analyses examined whether childhood abuse or neglect moderated these effects. Adults with elevated BP (n = 201; ≥120/80 mmHg) were randomized to MB-BP (n = 101) or enhanced usual care (n = 100) and followed for 6...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie May 1, 2026 Carla Fonseca, F. Gouveia, Soraia Silva et al.
Depression is a highly prevalent and incident mental illness. Current pharmacological therapies fail in approximately 30-40% of patients, highlighting the urgent need for novel agents with pleiotropic effects. This preclinical study aimed to identify new antidepressants and cognitive modulators among five phytocannabinoids: cannabichromene, cannabidiol, cannabidivarin, cannabigerol and...
Nurse Education in Practice May 1, 2026 Bin Shen, Jianjiang Liu, Qiaoxia Lv
AIM This updated systematic review and meta-analysis aimed to evaluate the effectiveness of mindfulness-based interventions (MBIs) in reducing stress, anxiety, depression and improving mindfulness among nursing students. BACKGROUND Nursing students often experience significant psychological distress due to the demanding academic and clinical environments of nursing education. MBIs have been...
Pregnancy May 2026 Riane Bradbury-Huang, Lindsay Quinn, Ellen L Tilden et al.
Previous research has shown that preventive counseling for women at high risk of perinatal depression leads to a reduction in the development of perinatal depression and is cost-effective. Barriers of cost, transit, time, and staffing limit accessibility of these services. We examined whether a theoretical, virtual, group, social worker (SW)-led Mindfulness-Based Cognitive Therapy (MBCT)...
Acta Psychologica May 1, 2026 Cristina Martinez Montes, Birgit Penzenstadler
Knowledge workers often face high stress due to deadlines and overcommitment, which negatively impacts their well-being. They have specific characteristics and challenges, such as a tendency to work in isolation or in intense team environments, sleep deprivation, and making decisions under pressure. To support preventive measures, this study provides a comprehensive, systematic understanding of...
Behavior Therapy May 1, 2026 Yanjuan Li, Amy Hu, Yiran Ding et al.
This study used a daily diary method to examine the temporal relationship between distress tolerance (DT), anxiety, and depression during a mindfulness-based intervention (MBI). A total of 83 participants with high emotional distress completed daily diaries of mindfulness, DT, anxiety and depression over one week before, during, and after the intervention. Linear mixed models showed significant...
Journal of Clinical and Diagnostic Research May 1, 2026 Ram Kumar Gupta, Abhishek Kumar Bhardwaj
Introduction: Recent rapid technological advancements and societal changes have dramatically transformed modern life, leading to a significant increase in mental health concerns. Meditation, an ancient practice, has gained considerable attention in recent years for its psychological and neurological benefits. Aim: To compare levels of depression, anxiety and stress between Meditation...
Revista Brasileira de Psiquiatria May 1, 2026 Marcelo Pinheiro Machado Adelino, Julia Diniz Grossi, Marcel Vella Nunes et al.
To synthesize evidence on pharmacological treatments for major depressive disorder (MDD) to inform updated Brazilian clinical guidelines. This overview included systematic reviews and meta-analyses published in the last 10 years, identified through MEDLINE, Cochrane Library, and SciELO. Eligible studies involved adults with MDD receiving pharmacological interventions. Risk of bias was assessed...
Cancer Reports May 1, 2026 Sepideh Hajivalizadeh, Kimia Farahmand, Kimia Kazemzadeh et al.
Depression is a prevalent comorbidity in cancer, yet conventional treatments show inconsistent efficacy. This review sought to provide a mechanism-based framework for managing cancer-related depression by exploring its unique pathophysiology and evaluating promising pharmacotherapies based on their alignment with these biological pathways. This narrative review synthesized evidence on promising...
The Brown University Psychopharmacology Update May 1, 2026
Patients with treatment‐resistant depression who received a series of treatments with ketamine or esketamine showed a substantial reduction in emergency department visits related to suicidality over a 6‐month period, a study has found. Study participants had a 56.7% response rate of depression symptoms following the acute phase of treatment.